text:
This is a case that relates to AT&T Mobility's practice of charging customers for taxes, fees and surcharges on internet access through certain services. These services include iPhone data plans, Blackberry data plans, other smart phone data plans, laptop connect cards and pay-per-use data services. The lawsuit alleges that these practices are not permitted under the Internet Tax Freedom Act, 47 U.S.C. § 151 (1998) (as amended) and other state laws. As a result, the lawsuit claims that AT&T Mobility is liable for damages to the Class. AT&T Mobility denies that it did anything wrong, denies that it violated any laws, and raised a number of defenses to the claims.
The Court did not decide in favor of the Class Representatives or AT&T Mobility. The lawyers who initially brought this case, referred to as "Class Counsel," have investigated the facts and applicable law regarding the Class Representatives' claims and AT&T Mobility's defenses. The parties have engaged in lengthy negotiations in reaching this Settlement. The Class Representatives and Class Counsel believe that the proposed Settlement is a good deal for the Class. The Court agreed, deciding under the appropriate legal standards that the proposed Settlement is indeed fair, reasonable and adequate and in the best interests of the Class. Both sides agree that, by settling, AT&T Mobility is not admitting any liability or that it did anything wrong, but both sides want to avoid the uncertainties and high cost in time and money in litigation of this type.
Class actions are lawsuits in which the claims and rights of many people are decided
in a single court proceeding. Representative Plaintiffs ("Class Representatives")
are named in the lawsuit to assert the claims of the entire class. This avoids the
necessity for a large number of people to file similar individual lawsuits and enables
the court system to resolve similar claims in an efficient and economical way. Class
actions provide a vehicle whereby people with similar claims are treated alike.
In a class action, the court is guardian of class interests and supervises the prosecution
of the class claims by class counsel to assure that the representation is adequate.
Class Members are not individually responsible for the costs or fees of counsel,
which are subject to court award.
You are a part of the Settlement if you paid taxes, fees or surcharges to AT&T Mobility
on internet access through certain services including iPhone data plans, Blackberry
data plans, other smart phone data plans, laptop connect cards and pay-per-use data
services on bills issued from November 1, 2005 up to and including September 7,
Excluded from the Class are (i) AT&T Mobility, any entity in which AT&T Mobility
has a controlling interest or which has a controlling interest in AT&T Mobility,
and AT&T Mobility's legal representatives, predecessors, successors and assigns;
(ii) governmental entities; (iii) AT&T Mobility's officers, directors, agents and
representatives; and (iv) the Court presiding over any motion to approve this Settlement
The following is a list of the internet access services included in the Settlement:
Plan Category and Primary Features/Characteristics
Data Connect Plans Web access and ability to send and receive internet e-mail
through a computer equipped with a laptop data card.
Smart-phone Data Features "Bolt-on" Web access and ability to send and receive
internet e-mail.
Smart-phone Standalone Data Plans Web access and ability to send and receive
internet e-mail.
iPhone Data Plans Web access and ability to send and receive internet e-mail.
Personal Blackberry Plans Web access and ability to send and receive internet
e-mail; also includes access to Blackberry APN, which provides push e-mail, and
contacts/calendar synchronization through RIM server.
Enterprise Smartphone Plans (using RIM/Blackberry, Goodlink, or Microsoft application
provider) Same as Personal Blackberry plans, and also provides enterprise
customer's end users the ability to send and receive internal and internet e-mail
to and from e-mail addresses provided by the enterprise customer.
If you determine that you are a member of the Class, you may receive benefits under
the Settlement. Essentially the Settlement benefits are three-fold:
First, AT&T Mobility will stop collecting the taxes it has been collecting
and paying to states, counties and cities. AT&T Mobility will not collect the tax
again unless the applicable laws of the United States or a state change or such
laws are interpreted to require or permit AT&T Mobility to begin collecting the
taxes again.
Second, AT&T Mobility, at its sole expense, will prepare and process tax
refund claims for filing with the various taxing authorities (e.g., state or county
or municipal taxing agencies) seeking a refund of the Internet Taxes collected by
AT&T Mobility from the Settlement Class and paid by AT&T Mobility to the taxing
jurisdictions. AT&T Mobility and/or the Class Representatives will file the refund
claims. The refund claims will be based on the amount of taxes each account holder
paid to AT&T Mobility. As part of the Settlement, AT&T Mobility has assigned its
rights, title and interest in such refunds to the Settlement Class to settle the
claims made by the Class. Significantly, AT&T Mobility has agreed to pay the money
owed up front, even if a taxing jurisdiction issues future tax credits to AT&T Mobility
in lieu of a refund of monies sought on a refund claim for Internet Taxes. Thus,
AT&T Mobility has agreed to pay the credited amount to the escrow accounts established
pursuant to the Settlement. If the use of the future tax credit will be spread over
a three (3) year period or less, AT&T Mobility shall pay monies to the escrow accounts
equal to the total future tax credits. If the use of the future tax credit will
be spread over a period longer than three (3) years, AT&T Mobility shall pay monies
to the escrow accounts based upon a payment formula. Under this formula, the payments
are equal to the net present value of such future tax credits of the fourth and
succeeding years using a 5% discount rate to compute the net present value. The
amount of the first three (3) years shall be paid with no discount.
Third, AT&T Mobility has agreed to pay to the Settlement Class any vendor's
compensation. Vendor's compensation is the amount of money AT&T Mobility was allowed
to retain from the sales tax it collected as compensation for collecting the taxes
for some (but not all) taxing jurisdictions. Vendor's compensation paid under the
Settlement does not include amounts to which AT&T would have been entitled independent
of the collection of Internet Taxes based on limitations on the amount of credit
allowed pursuant to applicable law. All refunds or payments by AT&T Mobility related
to credits and payments of the vendor's compensation will fund separate escrow accounts
for the benefit of the Settlement Class.
Payments to Settlement Class Members will be made only after all of the refunds/credits are made from each taxing jurisdiction in each state and after deduction of Court approved costs, expenses and attorneys' fees and Class Representative Compensation.
The Settlement Administrator will send out the benefits as soon as monies are received from the taxing jurisdictions to which your payments to AT&T Mobility were remitted. This may take some time, so please be patient.
The attorneys representing the Class, and their addresses, are shown in the response
to question 13 above. These lawyers are called Settlement Class Counsel.
The Court has approved the attorneys' fees, expenses and Class Representative Compensation to be paid from funds received from the refund claims and AT&T Mobility. Those approved amounts are deducted from the amount due the class before checks are issued.
More information is available on this website. You can read the Settlement Agreement
by clicking here. Or you may view the papers filed in this
Lawsuit during regular business hours at the office of the Clerk of the Court, United
States District Court for the Northern District of Illinois, Eastern Division, Everett
McKinley Dirksen United States Courthouse, 219 South Dearborn Street, Chicago, IL
60604. File: In Re: AT&T Mobility Wireless Data Services Sales Tax Litigation,
MDL No. 2147, Case No. 1:10-cv-02278. You can also call 1-877-905-8928 for information.
The full Settlement Agreement and the pleadings filed in the Actions can be requested,
in writing, from Class Counsel. Addresses for Class Counsel are available in the
response to question 13 above.
No. The legal fees associated with the Settlement and the costs of administering
the fund, etc. will be deducted from each Class Member's share of the Settlement.
The amount you may receive also will be affected by the taxing jurisdictions' decisions
on the refund claims. Finally, the amount of your benefit payment will depend upon
the amount of the tax that you were charged, and that amount depends upon the type
of service you had and the particular state and/or local taxes you were charged
based on your location.
No. You do not need to do anything. AT&T Mobility can identify who was assessed
taxes and the amount of those taxes. However, if you change your billing address,
please send written notification of your old and new address, along with your account
number(both current and if applicable, old/inactive) and phone number to the Settlement
Administrator using the following address:
ATTM Settlement Administrator
P.O. Box 57098
Washington DC, 20037-7098
If you desire to be in the Class, please do not send any materials to Class Counsel
or the Settlement Administrator. Do not mail copies of bills or other correspondence.
This will not aid in the payment of benefits and may lengthen the time and cost
of administering the payments.
If you have questions, please do not contact the Court or AT&T Mobility, but review
all materials on this site.
The Settlement Administrator will issue you a check and mail it to the most recent
address the Settlement Administrator has on file.
Please continue
to check www.attmsettlement.com
for details regarding the Settlement. If you are a valid Class Member and have provided
your current address to the Settlement Administrator, you will receive a refund
The Settlement is final and all court proceedings are complete. Any opportunity to exclude yourself or object to the settlement have expired and you are now included as a member of the settlement class.
You should cash the check. The check is full payment of the amount due you for your refund of sales taxes that were improperly collected from you by AT&T for certain services involving internet access. This is payment in full of your tax refund in this case. This check is a cash refund to you. Cashing the check does not obligate you to buy any product or service, now or in the future. It is the same as cash. If you do not cash the check within 180 days of the date on the check, the check will expire and will no longer be valid.
The Court approved the settlement on the assurance that every eligible class member would receive the net tax refund to which they are entitled, no matter how large or how small.
No. The sales taxes that were improperly collected from you were sent by AT&T to your state taxing authority. Class members receive their refund checks only after their taxing jurisdiction has approved and fully refunded these taxes. People who receive a check live in a jurisdiction where the taxing authority has approved and fully paid the tax refund. If you have not received a refund check, your taxing authority may be disputing the refund or may still be processing the refund request.
We recommend that you first take the check to your bank or other financial institution to see what documentation they require in order to accept the check as it is. If your financial institution will not accept the check, or if you are unable to comply with their requirements, then you may request that the check be reissued using the following procedure. A check can only be reissued if you provide the documentation listed below:
If you are the surviving spouse or surviving parent/legal guardian, please provide:
1) Check number
2) Copy of Death Certificate indicating you are the surviving spouse or surviving parent/legal guardian
For all other situations, please provide:
1) Check number
2) Copy of Death Certificate
3) Copy of legal documentation showing you are authorized to act on behalf of the estate.
Examples of documents that satisfy this requirement:
-Documentation showing the appointment of an Executor, Administrator, or Personal Representative of the Estate
-Probate order identifying the heirs to the estate
-A last will and testament that has been approved through a probate order
In addition to the documentation above, please also provide the correct payee name and address for the reissued check with your correspondence. The requested documentation can be emailed to: firstname.lastname@example.com or sent to:
ATTM Settlement Administrator
PO Box 57098
Washington, DC 20037-7098


text:
firstname.lastname@example.com writes:
> Does anyone know of a way to start PuTTY and SSH to a box by clicking
> on the IP address in a HTML application that I built (Sort of like
> following a href link)?
appears to have the skinny. You'd likely need to register the
ssh://user@host URI scheme with the web browser for it to possibly work.
Todd H.

subset: commoncrawl


text:
London City Airport weather map
- Recent locations
Your chosen location:
City of London
An error has occurred.
Weather type
Forecast summary
Regional forecast for London & South East England
Showers or longer spells of rain, mainly across the west.
Many places remaining dry with bright or sunny intervals, although showers or longer spells of rain will arrive at times, these mostly across the west of the region. Generally average temperatures, after a fairly chilly start in some rural locations. Maximum Temperature 19 °C.
Mainly dry at first, but overnight outbreaks of rain will spread east, perhaps becoming locally heavy. It will be milder, for most places, compared to last night. Minimum Temperature 12 °C.
Generally cloudy with patchy rain, mainly light, until the evening when dry and clearer conditions arrive from the northwest. Maximum Temperature 19 °C.
Outlook for Wednesday to Friday:
Breezy and mainly dry for Wednesday, with sunny spells. Thursday a band of rain will move slowly southeastwards, clearing Kent overnight and leaving sunshine and isolated showers for Friday.
Updated at: 0450 on Mon 26 Sep 2016
UK forecast for the next 5 days
Staying unsettled with outbreaks of rain and strong winds.
Heavy rain will move in from the southwest through today, affecting Wales and the southwest in particular. Northern Scotland and Northern Ireland will stay driest and brightest but some showers are likely to develop here.
The rain will continue across most south and central areas tonight, perhaps with some heavier bursts. Towards dawn occasional rain will affect many but it'll be mild for most.
Tuesday will start grey and damp with patchy rain across western parts. Locally heavy rain will clear to the east later but it'll be windy in the north.
Outlook for Wednesday to Friday:
Windy for most on Wednesday with rain and coastal gales in the north. Rain will clear south-eastwards through Thursday and Friday with sunshine and blustery showers following.
Updated at: 0450 on Mon 26 Sep 2016
Outlook for the UK over the next 6-30 days
UK Outlook for Saturday 1 Oct 2016 to Monday 10 Oct 2016:
The weekend will be breezy, with a risk of gales at times in the north and west. Showers or longer spells of rain are likely, which will be most persistent in northern and western parts, with the best of any bright spells in the southeast. Changeable conditions are expected to continue through the rest of the period with mainly west or southwesterly winds dominating. This will bring showers or longer spells of rain, interspersed by some brighter periods. The most persistent rain occurring in the northwest, where there is also the risk of occasional gales. Some good brighter spells are possible in the southeast. Temperatures a little below average at first, but then rising to near or above average in the south, and perhaps also at times further north.
Updated at: 1205 on Mon 26 Sep 2016
UK Outlook for Tuesday 11 Oct 2016 to Tuesday 25 Oct 2016:
There is currently low confidence for the forecast during the second half of October. However, the most likely scenario is for a continuation of mainly west or southwesterly winds. This will bring changeable weather with showers or longer spells of rain, interspersed with some dry and bright periods. The north and west is likely to see the heaviest and most persistent rain, with also strong winds or gales at times. The south and east is likely to see the best of the dry and bright conditions, with the possibility of some more prolonged settled spells. Temperatures will vary through the period, but probably averaging out slight above average for the time of year, with an increasing risk of overnight frost in the more settled spells.
Updated at: 1205 on Mon 26 Sep 2016
Location Details
London City Airport
Location: 51.5048, 0.058
Altitude: 5.0 m above mean sea level


text:
After allegations of ballot tampering arose in Clackamas County, the Deschutes County clerk explained Monday what's being done to make sure a similar incident doesn't happen here.
Voters lined up to drop off their ballots in Bend on Election Eve.
"We're very busy," county clerk Nancy Blankenship said. "We've been busy since the moment we opened, and before that, we had phone calls and people waiting even before we opened."
Blankenship said almost 100,000 voters are registered in Deschutes County this election season and about 30 percent of them wait until the last minute to vote.
Once people drop off ballots, signatures are verified on the envelope, the election board reviews the ballot, and it's finally scanned by machines called tabulators.
But once a ballot reaches the counting room, how do voters know it's safe?
In Clackamas County this weekend, an election worker was accused of tampering with ballots, filling in Republican candidates on spaces voters left blank.
"I can't also talk about how she was caught, but I can tell you she was caught because of the security measures we have in place," said Oregon Secretary of State Kate Brown.
In Deschutes County, they're working to make sure similar troubles don't happen here.
"My reaction was the same -- I can't believe it's happening," Blankenship said. "But you know, the great news is, the process worked. The person was identified and no longer working, the Department of Justice is investigating, and it's going to be something that will impact this person for the rest of their life."
Each group counting the ballots is made up of five people from different parties.
"So you have four other people that are watching you, so that's one of the safeguards," Blankenship said. "Then we have seven boards working, with two election supervisors overseeing the process."
Blankenship said if registered voters still haven't received a ballot, it could be because people have moved and the office doesn't have updated information. Those people must visit the county clerks office to make the changes. Another reminder: People need to sign the back of the envelopes on their ballots.
County clerks making sure your vote counts
After allegations of ballot tampering arose in Clackamas County, the Deschutes County clerk explained Monday what's being done to make sure a similar incident doesn't happen here.
Copyright 2012 KTVZ. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
The views expressed are not those of this company or its affiliated companies. Please note by clicking on "Post" you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms.


text:
Swift snaps our best-ever ultraviolet image of neighboring Andromeda Galaxy
In a galaxy far, far away … about 2.5 million light years, in fact, lie approximately 20,000 hot, young stars and dense clusters that comprise the Andromeda Galaxy. The galaxy, known as M31 in the constellation Andromeda, was recently captured by an ultraviolet optical telescope aboard NASA's Swift satellite and delivers the highest-resolution view of a neighboring spiral galaxy ever attained in the ultraviolet.
NASA's Swift satellite spends most of its time in space searching for distant cosmic explosions but, for two months last year, took a sojourn from its usual duties to capture stunning views of the largest and closest spiral galaxy to our own.
"Swift reveals about 20,000 ultraviolet sources in M31," said Stefan Immler, a research scientist on the Swift team at NASA's Goddard Space Flight Center. "Of particular importance is that we have covered the galaxy in three ultraviolet filters. That will let us study M31's star-formation processes in much greater detail than previously possible."
The Andromeda Galaxy, is more than 220,000 light-years across and lies 2.5 million light-years away. On a clear, dark night, the galaxy is faintly visible as a misty patch to the naked eye.
Between May 25 and July 26, 2008, Swift's Ultraviolet Optical Telescope (UVOT) acquired 330 images of M31 at wavelengths of 192.8, 224.6, and 260 nanometers. The images represent a total exposure time of 24 hours and took up a massive 85GB.
Erin Grand, an undergraduate student at the University of Maryland at College Park, who worked with Immler as an intern this summer, spent ten weeks processing the data to create the images.
The images highlight some new insights into this galaxy. The first is the striking difference between the galaxy's central bulge and its spiral arms. "The bulge is smoother and redder because it's full of older and cooler stars," Immler explained. "Very few new stars form here because most of the materials needed to make them have been depleted."
Beyond the central bulge, dense clusters of hot, young, blue stars sparkle. As in our own galaxy, M31's disk and spiral arms are a breeding ground for stars because they harbor most of the gas and dust needed to produce them. Star clusters are especially plentiful in an enormous ring about 150,000 light-years across.
What triggers the unusually intense star formation in Andromeda's 'ring of fire'? Previous studies have shown that tides raised by the many small satellite galaxies in orbit around M31 help boost the interactions within gas clouds that result in new stars.
Bright light
In 1885, an exploding star in M31's central bulge became so bright it was visible with the naked eye. This was the first supernova ever recorded in any galaxy beyond our own Milky Way. "We expect an average of about one supernova per century in galaxies like M31," Immler said. "Perhaps we won't have to wait too long for another one."
"Swift is surveying nearby galaxies like M31 so astronomers can better understand star-formation conditions and relate them to conditions in the distant galaxies where we see gamma-ray bursts occurring," said Neil Gehrels, the mission's principal investigator at NASA Goddard.
Since Swift's November 2005 launch, the satellite has detected more than 400 massive, far-off explosions likely associated with the births of black holes.
Swift is managed by NASA Goddard. It was built and is being operated in collaboration with Pennsylvania State University, the Los Alamos National Laboratory in New Mexico, and General Dynamics of Gilbert, Ariz., in the United States.


text:
The latest version of Adobe Flash Player is required to watch this video.
Please click on the link below to download the latest version. Thanks!
Israeli officials have accused the United Nation's International Atomic Energy Agency of hiding incriminating evidence about Iran's nuclear weapons program, according to a report published by the Israeli newspaper Haaretz.
A senior Israeli official confirmed the story to CBN News and added Israel has severe concerns about the IAEA's reporting on Iran's nuclear program.
In an exclusive interview with CBN News, former Republican presidential candidatel Mike Huckabee addressed the threat of Iran's nuclear program.
"We need to recognize that the threat to Israel is a threat to the United States," Huckabee explained. "If Iran weaponizes nuclear material and were to use it or even get into the position where they could, it does pose a threat to more than Israel but to the entire balance of power and peace in extraordinary region of the Middle East and the world."
Huckabee also said that Israel should be allowed to protect itself from Iran's nuclear threat.
Log in or create an account to post a comment.
Are you seeking answers in life? Are you hurting? Are you facing a difficult situation?
Find peace with God, discover more about God or send us your prayer request.
Call The 700 Club Prayer Center at 1 (800) 823-6053, 24 hours a day.
A caring friend will be there to pray with you in your time of need.
CBN News is a national/international, nonprofit news organization that provides programming by cable, satellite, and the Internet, 24-hours a day. Follow us on Facebook, Twitter, and Google+.
More Info


text:
Wall Street Decline Takes Its Toll...
LC-MS Gains Favor Due To the...
Expanding Use of NGS Has Largely...
As Immunotherapy Revolutionizes the Cancer Treatment...
A nanopore-based sequencing platform that can control the passage of DNA and accurately distinguish between all four bases has been developed by researchers at the University of Washington and University of Alabama at Birmingham. They claim their achievement effectively overcomes both these two longstanding hurdles to the development of an accurate nanopore sequencing system.
The platform developed by Washington's Jens H. Gundlach, Ph.D., and colleagues, is based on an engineered form of the protein pore Mycobacterium smegmatis porin A (MspA), which is about 1.2 nm wide and 0.6 nm long. The MspA pore is incorporated into a lipid bilayer membrane bathed in potassium chloride, to which a voltage is applied to create an ion current flowing through the pore. Molecules translocating through the pore essentially generate a momentary, detectable change in current.
What makes this system so sensitive, however, is the integration of bacteriophage DNA polymerase (DNAP) phi29 into the pore, which effectively acts as a motor to pull the single-stranded template through the aperture one nucleotide at a time. While previous nanopore-based sequencing systems haven't been capable of accurately discriminating between the four different nucleotides, the MspA-phi29 DNAP platform slows down translocation through the pore just enough to allow the telltale signal generated by each of different nucleotides to be identified. "The motor pulls the strand through the pore at a manageable speed of tens of milliseconds per nucleotide, which is slow enough to be able to read the current signal," Dr. Gundlach explains.
The investigators report their achievement and experiments to confirm the system's sensitivity in Nature Biotechnology in a paper titled "Reading DNA at single-nucleotide resolution with a mutant MspA nanopore and phi29 DNA polymerase."
To save this item to your Favorites,
log into GEN Select.
We'll be sure to take you back here after you do.
Not a member of GEN Select?
To comment on this article,
log into GEN Select.
We'll be sure to take you back here after you do.
Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today's life science tools and technologies.
You're all set! Thank you for subscribing to GEN Highlights.
Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?
Be sure to add [email protected]
to your Address Book or Safe Senders List.
here for instructions.
If you have any questions about your subscription, click
here to email us or call at (914) 740-2189.
You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
© 2016 Genetic Engineering & Biotechnology News All Rights Reserved


text:
You can read the post or you can watch the video version of it here.
I told the Spectacular Asshole a secret the other day. It wasn't a huge secret to me, but it wasn't something that I necessarily want the whole world to know either. I didn't really think it over before I told him, but afterward I was glad I did because it was one of those things that you have to tell right away. If I didn't and it came out later it would have looked like I was hiding it and that would have opened up a big can of worms.
Anyway. So I told him, he was cool about it, and it was fine. No biggie. A couple of days later I just happened to mention to him that someone else knew about it and the shit hit the fucking fan. One minute we're having an off-handed conversation about nothing in particular and the next we're having a huge discussion about intimacy and privacy and what should be kept sacred between the two of us.
Well colour me blind-sided because I never thought that this particular secret would ever inspire such a conversation. In my mind, it was a relatively innocuous secret and definitely not – by my definition anyway- something private between us. But clearly Mr. SA and I have wildly different opinions of what defines an intimate conversation between us. Clearly.
So. While I was mulling that over, I received the following email from a new reader:
Was hoping to get a female perspective on this: What do you consider an intimate conversation between 2 people? Please share your thoughts.
Weird, right? Here I am sitting here puzzling around what should define an intimate conversation and here he comes asking me the very same thing! It was destiny.
That night when I got home from work I was still mulling things over when suddenly my phone rang. It was my bus driver; to whom I'd given my number in a fit of good-nature a few days before that because he was cool and funny. But after about 15 seconds of conversation I knew we were in for a problem. This dude came HARD (no pause) on the sex tip. Right out of the gate he talked about what he likes, what he does, and all the things he would do to me if he got me in bed. It was insane. And, frankly, hilarious. (check out the video if you want an example of the insane talks he was giving me). While he was going on and on there was but one thought in my head: this conversation is waaaay too intimate for two people who just met to be having.
Every once in a while the stars align in such a way so as to show me that I should be writing about something. And these three things all happening in one day was a sign to me that I should write about intimate conversations. But as I contemplated doing that I realized that I have no real definition in my head of what exactly intimacy is. I mean I get the obvious things like private details of sex with someone you care about, the fine details of your relationship problems. I get that those are things that should never be shared outside the confines of your relationship. But beyond that, it all seems to blurry to me. What makes a conversation intimate? The topic? Or our desire for it to be intimate? Does intimate conversation only occur among a couple or are there intimate details of a friendship, intimate conversations between siblings or e-boos that should never be taken outside the confines of those relationships? When we're talking about intimate conversation are we really just talking about secrets?
I don't have answers to any of these questions, but I'm hoping some of you do. So let's get a little discussion going today. Tell me how you guys define intimacy and whether you're only concerned about it when it comes to your romantic relationships or if there's intimacy involved in all your relationships? How important is it for each member of a couple to have the same definition of intimacy, and if they don't – whose opinion wins? Share your thoughts with me in the comments.
bag lady. digital nerd. beauty junkie. shoe whore. i'm a sucker for big words and box-fresh kicks. know a little bit about a lot of things and have something to say about everything.
Okay. So here's the situation: Boy meets Girl. They date, enjoy ...
In keeping with this week's apparent theme of how to behave in ...
So the homey Malik is back with another guest post. This time ...
If there's one thing that will get the "danger" ...
That's kinda tough. I think you should definitely be considerate of his feeling but I also feel that it's your prerogative to share what you want with who you want, as long as it's about you. Once it gets into stuff about the relationship, or your partner/friend/family member than you should consider everything an intimate detail unless otherwise stated.
It's kinda like how you're supposed to know your partner's love language. If you want to gauge how important you are to a person based on the things they tell you, you need to know the things that they consider private.
My brain isn't fully functioning right so I'll add more tomorrow if I think of anything else.
Yup, if it's not my man, I can talk about ME and MY ISH all I want. If you are part of the story, you're part of the story. I still respect people, but GTFOH with that keep my name outta your mouth talk. Keep yourself outta my lifespace and we'll have a deal, until then: my life, my prerogative to share it. #BobbyBrown
I just wasted 7 minutes of my life on that video… But I will say this…
Monday's video… please wrap your hair in a ponytail again… It reminds me of J Lo in "Enough"
And it seems like you aged 5 years from May 1st – May 9th…
I really don't have any real thoughts on intimacy right now… I'll just piggyback on someone who has better insight in the comments
Is this your attempt at being
Dr. J a rude asshole to get women?
It's not gonna work. You gotta build a portfolio first. Then you get to be an asshole.
When I am on these eStreets… I don't tell Adonis' brain what to do… And neither do you… He just…. does…
Thank you for the advice…
You know what, I believe this statement is true 100%.
This is your brain on blogs.
How'd that work out for the car? Someone's gotta be driving man…
"I just wasted 7 minutes of my life on that video"
You know Adonis, ordinarily I would let that slide, as I do so many of the other questionable things you say on here. But today I'm not in the mood to entertain your antics.
Luckily for you and for me I'm very tired this morning. Too tired for me to write a long diatribe about how ignorant and unnecessary it is for you to say (and tweet) some shit like that. I'm too tired even to point out that when you put out content at the rate at which I put it out, not everything is going to be the world's greatest video ever.
And I am WAY too tired to remind you that in the absence of you having your own blog or making your own videos, you really should shut the fuck up.
I'm too tired to get into it with you this morning. So instead I'm just gonna say that given the volume of tweets and comments you leave all over the blogosphere I'm pretty sure you had absolutely nothing better to do with those seven minutes than watch that video.
Max. With Teeth. I Like…
It still doesn't change the fact that I could have skipped the video…
Yup, you are absolutely right. You could have skipped the video and just READ the post instead.
Right? I did say the choice was yours right? Watch the video or read the post? If he didn't like the video why the fuck did he watch the whole thing?
Oh right – so he could talk shit.
I'm sorry but when a man tries to insult a woman's looks, icant. It doesn't matter to me whether or not you have a blog…I need you to have a PICTURE up before you comment on anyone's looks. Show your face.
And please don't refer to yourself in third person. That's psychotic.
CO-SIGN! Max, is so patient with this mofo. Reason 25642485785464679798425 I think she is dope.
maxie: lil' scrappy wants to play. Permission?
Wow Adonis you are out of control sometimes. I would have blocked your ass for that. Just an FYI.
Is there anyway to block this guy who would best be described as the result of a boring fuck?
And where is his blog or his videos or even a picture of him so I can comment on his forgettable looks?
We'll get there emti, no rush
@all Thanks for going to bat for Max… Not that serious, but I understand…
Enjoy guys
LMAO @ you calling me out for checking out your apartment
and yes, yes, I totally had already checked it all out! And it was fine, I was a bit relieved that it wasn't quite as perfectly simple as Wis's room. I feel like a slob compared to his serial killer clean pad.
Great questions. Firstly on your question re: the SA. When ya'll are together in a re-rrre-rah-rharlay-relationship, whoo that's hard to say, but anyway, when you're in one of those, I think there will have to be a compromise. Basically ya'll will have to sit down and have this exact convo. WHAT is sacred, and WHY? The why is important because you'll never be able to predict every topic that may come up, but if you know the spirit of why something is sacred to one another, then you can pretty much figure out all topics based on that.
Like to you, the sex stuff isn't all that secret. It's sex, it's physical, it's friction, and it makes for seriously juicy storytime (your form of intimacy with your girls). But to him, it's…whatever it is to him. (I assume he thinks your friends are judging, but I'm not a man, so I really have no clue. And men, if you are ascared of the judgment, don't be, most times we're dying of jealousy just that someone is even GETTING some dick!)
For instance…an exlove of mine shared something personal about his family with me. He never said it was a secret. He never asked me not to tell anyone, but this was big. This was his family, this was something he hadn't even told his boys. That was sacred, incredibly intimate, and I didn't share it because I knew his "why".
I think it's important that you don't lose YOU in this negotiation either though. There are things that you need to share too. To vent, to get feedback, to have someone to talk to besides just your man, to maintain your existing relationships, and fulfill your own needs. Plus, you know you. You can promise to not share anything with your friends if you want to, but that doesn't mean you're going to be able to stick to that agreement…best you fulfill a reasonable agreement than to agree to the world and just renege and lie to him. It won't be an easy convo,
What makes a conversation intimate?
For me, it's about a level of comfort I guess. When you're about to share something that I told you ask yourself, "if PersonA were there when Star told me this, would she have still revealed it?" if not, don't tell PersonA. If so, share away. So with SA. If he were in a group of your girlfriends, would he be ok with overhearing you say, "So he tried this new move, where I put my legs behind my head so that they're out of the way and kinda tries to spin me like a top, he calls it 'Inception' – but he totally couldn't get any spin going. It was awkward and embarrassing. He just wacked off and went to bed." Yeah, no. Not many men would be cool with that. He might be ok with, "Man we tried some crazy new ish last night. My baby's always trying to spice ish up" and leave it at that. That he'd prolly be cool with. That's my general rule of thumb, if they were here, would I say the same ish? Yes? Then I'm cool.
Intimacy is not just for couples. No ma'am. Intimacy can happen with anyone. It won't happen with everyone, but the possibility is always there. Total strangers at Ground Zero on 9/11 holding hands, silently feeling each other's pain. The familiar look of desperation, frustration, joy, and exhaustion briefly exchanged between two new mothers. When you reassuringly touch the hand of a coworker that's just been diagnosed with cancer. When a new friend trusts you to perform impromptu surgery on her toe to remove a splinter. That moment when your man let's his guard down and does the lil dick dance in front of you without a care in the world. All that ish is intimate.
Great questions. I hope the discussion is as good as the post…
and that I didn't use up all the characters allowed for this site in one day and that at least ONE person makes it through all these keystrokes!
and when another friend lends you the tweezers to remove said splinter….
Yes! 🙂 Even the bond shared between two gals that love nothing more than a sale!
And Bath & Body Works 😉
What makes a conversation intimate? The OPPOTUNITY to be oneself WITHOUT judgement from the other–PURE acceptance of BEING oneself
The topic? Irrelevant…
Or our desire for it to be intimate? Most def… ALL of us want to be ACCEPTED for whom we REALLY are… (smile) Although a lot of us FAKE so much that we only end up fooling ourselves along with everyone else… Tragic… (shrug) Better to keep sharing the REAL person…
Does intimate conversation only occur among a couple or are there intimate details of a friendship, intimate conversations between siblings or e-boos that should never be taken outside the confines of those relationships? Intimate conversation CAN happen between TWO people–REGARDLESS of their…"relationship"
When we're talking about intimate conversation are we really just talking about secrets? Nope, not at all… (smile) At least NOT with the Symbiotic Loner…
I really like this: "What makes a conversation intimate? The OPPORTUNITY to be oneself WITHOUT judgement from the other–PURE acceptance of BEING oneself"
Intimate talks: Baring one's soul in a direct way without the aid of self-deprecation or asides to distract from what you're trying to communicate.
I think intimate, as in close and deeply personal conversations can happen across the board from romantic partners to good friends to close fam members.
I think that if its something someone shared with you in confidence then it should stay with you, it's not necessarily about secrets but moreso trust.
Wow this is a tough one. I'm a complete open book so my level of intimacy is probably not the most common. I will say I dated a very shy/reserved man for years and I learned to not share anything that has anything to do with him/us. Just a bunch of "we're doing fine, he's fine, etc" apart from talking to my mom and bestie cause they're my lifeline. When it comes to sharing info about myself, I overshare and he didn't like it. We'd leave get togethers with him asking "why did you tell them that? keep somethings to yourself." etc. I just tried to find a balance. When it comes to yourself, you know what you're comfortable with. You're a smart woman. If you're fine with your level of sharing, then he should be too unless it concerns him. If you guys grow into something, I would try to consider his opinion without losing who you are. I'll cosign Star in if you wouldn't say it in front of him, then that would be defined as intimate. I share intimate details with my mom but I trust her. This whole intimacy thing is a tough one and a work in progress as you get to know your partner.
Great topic and vid Maxie!
Not sure if I have an answer either. I definitely don't consider secrets to be the deciding factor of intimate talks. I do think there is an intimacy level involved in most relationships that aren't artifical. And I believe that varies from each relationship. When in a romanitc relationship, I do think it's important for both parties to have a clear understanding about what they prefer not to be shared outside of the relationship. The one thing that comes to mind is sex.
Im gonna think on this some more.
Hmmm I get where he's coming from in regards to not sharing intimate details that pertains to him BUT at the same time he knows your life is basically an open book (blog) and judging from what you said on your video you do know/have boundaries, I mean its NOT like you divulging how big or small his pecker is or what his facetime status is and it's not like you dropping goverment names either.
It sounds to me as if he's getting a little Caught Up. No????? He's mad because you shared an ID about YOURSELF with him and then told someone else and now he doesn't feel Special.. Sounds like feelings to me girl, but hey I could be wrong.
I think SA already had some type of feelings, hence the re-entrance.
Many do not know what the term "intimate" means. So although intimate is an adjective it also needs to be qualified. I could give you several examples but probably none better than this, I was talking to my college chapter's new president and I said, "expect our conversations to become more intimate." While he knew what I meant because i'm also a past president, some younger brother said, "PAUSE." And I said, "No. Intimate only means more personal than just informal conversation." Anyway, for that reason it's hard to answer to this post. I think that intimate relationship details should only be discussed with those in the relationship. But this wasn't even something that pertained to this relationship, so really it's whoever Max has determined has the right to the information. Besides, are they even in a relationship anyway for him to be making demands and rules?
I think that I am having my own boundaries with what is exactly intimate being tested at the moment. I will sit this one out and read the responses of others.
I don't think intimate always means private. So an intimate conversation where you tell your secret someone else, I don't understand why he would trip.
Maybe he meant that he wishes to (feel like he) share(s) something only specific between you two and the conversation following was only a side-effect of that desire.
It is suggested to stay away from sweets are they are
rich in calories and carbohydrates. This is important as high levels of protein will help
you to feel full for longer periods of time and prevent muscle loss from a
lower calorie diet. There are a lot of of
them that in the event you get suckered right into these 6
pack abs workout scams, you can expect to go under more rapidly than a improperly organized enterprise.


text:
PITTSBURGH - Natural gas processors MarkWest Energy, Dominion Resources, M3 Midstream and others are building about $12 billion worth of infrastructure in Ohio, according to an official with the state Department of Natural Resources.
While Rick Simmers, chief of the Division of Oil and Gas Resources Management at ODNR, spoke Friday during the DUG East conference in Pittsburgh, he noted a case before the Ohio Supreme Court is challenging his agency's exclusive authority to regulate drilling and fracking throughout the Buckeye State.
Simmers reminded those in attendance at the two-day conference that although advances in horizontal drilling and fracking now allow for exploration in the Utica and Marcellus shale formations, there have been about 280,000 wells drilled in Ohio since 1861.
"We believe regulation is best at the state level," Simmers said, noting the city of Munroe Falls in Summit County remains determined to gain some authority over fracking.
In 2004, the Ohio General Assembly gave the state DNR "sole and exclusive authority to regulate the permitting, location and spacing of oil and gas wells." However, Ohio Supreme Court Chief Justice Maureen O'Connor recently agreed to accept Munroe Falls' appeal, so the matter is pending.
Simmers said Ohio Gov. John Kasich takes fracking regulation seriously. He said seismic activity near an underground injection well in the Youngstown area a couple of years ago led to more stringent rules regarding where drillers can place such wells.
"Gov. Kasich said this must be done properly," Simmers said. "He asked if we had enough staff. At that time, we didn't."
Simmers also said the population density of the area of Ohio in which fracking is happening is relatively high, especially compared to that of states such as North Dakota or Texas.
This causes more problems because people may complain about the activity, he said, such as if someone reported natural gas flaring as a fire to public authorities.
"This creates a real regulatory problem," he said.
Also Friday, Paul Weissgarber, senior vice president of Crosstex Energy, said that "condensate" that companies such as Chesapeake Energy, Gulfport Energy or others may report during production is "a very light oil."
"The bulk of this is gathered at the well pad. Some of it drops off into the pipeline, while some drops off in compressor stations," Weissgarber said.
"There is this myth out there that everyone who works in this industry is coming from Texas. At least for us, this is not the case," he added.


text: This song is simple, short, slow and really loopable. It's melancholic but also sweet and it's similar to chamber music in classic style. The main instruments are: clarinet, oboe, strings, flute and bassoon. This music has the flavor of a pending and the melody is delicate. Especially the bassoon evokes an ancient and intellectual place like a library. However, a veil of sadness wafts in this environment.


text:
New subscription
Renew my subscription
Give a gift
Pay my bill
Change my address
Active within 2367 Days
Hi! My name is TJ
I am a Manx from Glen Allen, VA
Nicknames: Bunny Butt
Age: 9 years old
Gender: M
Coat: short haired
Education: King of catching bed toes.
My favorite tricks and treats are: TJ will stand up to be petted. and Tuna, Tuna and more Tuna. But he has just discover paper.
Where I hang out: Loves to just be in the room with others.
My favorite grubs: Treats. Any kind of treats
My pet peeves: Doesn't understand why Buttons doesn't love him.
What I love about my owners: My new Mom loves to give me individualized attention. I love when she scratches my ears and pets me.
My cat hobbies: TJ loves toys. He has discovered all the cat toys in the house and is finding toys that even I did not know existed, like a stuffed polar bear.
Pet motto: I never met a toy that I did like.
See all awards »
One of my past clients was selling her Mom's house and when I went on the appointment he just hung out next to me. All the kitties there needed to find new homes. TJ won me over and the next time I went to the house, he came home with me. Then he met the rest of the kitties and the fur flew till they all adjusted.
I've had 1573 friends visit me.
I'm the 32,460th member on CatChannel.com.
13 friends have voted for me since I joined Club Cat!
Come visit me, Bart and Peach State Cats & In Loving Memory~.
Come visit me, Cocoa, Huggums & Kisses.
Come visit me, Tommy.
Come visit me, Molly.
Come visit me, Bandit & Emma.
Come visit me, Wahine loves Spooky!, Opal, Derby, Caspurr Kenny, Sweetheart, Angel Thomas, Kritter Face & Izabelle.
Come visit me, pete & Tiger.
Come visit me, Jake & Sabrina.
Tell a Friend |
Report inappropriate content on this page.
Hi, my name is
A. Frosty-Prayers for all of our furiends!.
Visit the photo gallery to cast your vote »
Get quick tips for happy cats, food recall info, news alerts and best behavior advice.
Sign up to get updates delivered straight to your inbox.
CatChannel takes your privacy seriously. To learn more, please read our privacy policy.


text:
Steelhead Report, Jan. 20
Streams are low and clear, and anglers have had moderate success on the lower parts and mouths of the streams. Anglers enjoyed decent hauls at the lower section of Walnut Creek. Steelhead in Elk Creek are scattered.
Cold temperatures this week could produce ice and slush on the creeks. Bait fishermen have been using eggs and minnows, while fly fishermen are using sucker spawns.
Poor Richard's Bait & Tackle, 6821 West Lake Road, 474-5623; Elk Creek Sports Store, 105543 Old Lake Road, 774-8755
NOTE: This is the final Steelhead Report of the season.


text:
Iowa true freshman place kicker Mike Meyer was awarded special teams player of the week honors from the Big Ten on Monday.
Meyer connected on four field goals, including a career-long 42-yarder, to account for 12 points in Iowa's 18-13 victory at Indiana. The freshman kicker booted field goals of 23, 27 and 27 yards before hitting a 42-yarder early in the fourth quarter to pull the Hawkeyes within 13-12.
Iowa would tally a late touchdown for the victory. Meyer picks up the first weekly laurel of his career.
The last Iowa player to win special teams honors from the Big ten was Paki O'Meara, who was named on Sept. 7, 2010.


text:
We're More Then Just Trophies...Great Ideas for all Occasions!
Make your business stand outCheck out our promotional items
We can help you with one item or a hundred-We now have a complete catalog online for advertising and promotional items. We have local delivery available for $5.00.
Please read the item for additional charges such as engraving, logos or set up charges. By going to the checkout page they can be figured for you.
Our rmail address: firstname.lastname@example.com


text:
Conference Menu
Formulation Strategies for Improved Delivery of Biologics Day 1 | Day 2
New Technologies for Biologics Delivery and Targeting Day 1 | Day 2
Attendee ListSpeaker BiographiesPDF DownloadShort CoursesPostersPodcastHotel & TravelSponsor & ExhibitPress PassRequest Brochure
Formulation Strategies for Improved Delivery of Biologics Day 1 | Day 2
New Technologies for Biologics Delivery and Targeting Day 1 | Day 2
Attendee ListSpeaker BiographiesPDF DownloadShort CoursesPostersPodcastHotel & TravelSponsor & ExhibitPress PassRequest Brochure
Student Fellowships
Corporate Sponsors
Media Sponsor
Media Partners
Formulation Strategies for Improved Delivery of Biologics Conference
Julia Rashba-Step, Ph.D., Senior Director, Novel Delivery Technologies, Pfizer, Inc.
Julia is responsible for developing the strategy and managing the Novel Drug Delivery activities for Pfizer's BioTherapeutics Pharmaceutical Sciences. The position plays a major role in designing and supporting the BioTxDevelopment strategy and is a key driver for the life cycle management process for BioTx products. In addition to developing the technologies for advanced delivery formulations, Julia also supports activities of novel device evaluation and development.
Prior to joining Wyeth ( later acquired by Pfizer) organization, Julia worked at Epic Therapeutics, a wholly owned subsidiary of Baxter Healthcare Corporation as a Director of Research and Development and later as an Alliance Management Director. In this role Julia was responsible for managing all technical and business aspects of collaborations with partners including out-licensing of proprietary PROMAXX technology.
Julia received her PhD in Biophysics from Russian Academy of Sciences, worked at Mount Sinai Hospital, NY and University of Southern California before transition in the industrial environment. Julia's background is in formulation, delivery and process development of biologics. Julia's expertise and interests are in multiple areas of advanced formulation and delivery such as sustained release, non invasive delivery, high concentration formulation, targeted delivery and innovative devices.
Julia is a member of multiple professional organizations including serving on the Advisory Board of Drug Delivery Partnerships, CRS Nominating Committee and mentoring group through HBA (Healthcare Business Woman Association).
Sujit K. Basu, Ph.D., Senior Director, Drug Product Development, Shire Human Genetic Therapies
Sujit Basu joined Shire in 2012 and currently serves as Senior Director, Pharmaceutical Development. Dr. Basu has more than eighteen years of industry experience in pharmaceutical R&D, project management and cGMP manufacturing and is an inventor or author of more than 50 issued patents and patent applications and peer-reviewed publications. Before joining Shire, Dr. Basu was Vice President, Formulation at Dicerna Pharmaceuticals, responsible for nucleic acid formulation and delivery. Prior to that, Dr. Basu was Sr. Director, Formulation and project team leader at Altus Pharmaceuticals, responsible for developing drug products utilizing protein crystallization and formulation technologies and CMC team leader and staff scientist at Alkermes, responsible for developing inhalation and injectable drug products. Before coming to the USA he was a pharmaceutical manufacturing manager at Sarabhai Enterprises in Baroda, India, responsible for developing and commercial manufacturing of oral and injectable drug products.
Dr. Basu holds a B.S. in Pharmaceutical Technology and a M.S. in Pharmaceutical Engineering from Jadavpur University in Kolkata, India, a Ph.D. in Pharmaceutical Sciences from the University of Southern California, Los Angeles, and a Certificate in Management from Harvard University.
Nathan J. Alves, Ph.D., Post-Doctoral Research Fellow, Indiana University School of Medicine, Indiana
Nathan Alves is a Post-Doctoral Research Fellow at the Indiana University School of Medicine (IUSM) in the Emergency Medicine Department. His current research interests are primarily in nanoparticle based pharmaceuticals for the clinical treatment of pulmonary embolism, blood clots in the lungs, in Dr. Jeffrey Kline's lab. Prior to joining IUSM in 2013, he received a PhD in Chemical and Biomolecular Engineering at the University of Notre Dame and MS and BS degrees in Biomedical Engineering from the University of Rochester in 2008 and 2007, respectively. The research he has conducted, while spanning many disciplines, is centered on the development of translational technologies, treatments and techniques that can be utilized to have a positive impact on people's lives. His graduate research was focused on how an underutilized, highly conserved binding domainlocated on the antibody variable fragment known as the nucleotide binding site (NBS) can be implemented to improve antibody purification, advance medical diagnostics, and to develop next generation antibody/nanoparticle based therapeutics. Having major contributions to 4 patent pending antibody and nanoparticle based delivery technologieshe also received a 1st Tier Baxter Young Investigator award as an up-and-coming mind in science in 2013.
Morten J. Maltesen, Ph.D., Project Manager, Biopharma Application Development, Novozymes Biopharma
Morten J. Maltesen joined Novozymes in 2010 as a Research Scientist. He earned his MSc in Engineering (specialized in Biotechnology) from the Technical University of Denmark combined with his PhD in Pharmaceutical Sciences from University of Copenhagen. In his current role as
Project manager, Dr. Maltesen works on slow-release formulations based on recombinant hyaluronic acid and on formulation and drug delivery of peptide based drugs. Before joining Novozymes Biopharma, Morten worked as a research scientist in early drug development.
Sabiruddin Mirza, Ph.D., Sr. Research Associate, School of Engineering & Applied Science, Harvard University
Sabiruddin Mirza is currently a Senior Research Fellow at the School of Engineering and Applied Sciences at Harvard University, Cambridge, MA, USA, and an Adjunct Professor at the University of Helsinki, Helsinki, Finland. Dr. Mirza received his M.S. degree in pharmaceutical chemistry from the Ukrainian Pharmaceutical Academy, Ukraine, in 1994 and began his professional career in the pharmaceutical industry as a production pharmacist. After several years in full-time industry, he escaped to academia and earned his Ph.D. degree in pharmaceutical technology from the University of Helsinki in 2007. His dissertation research has been awarded the 2008 American Association of Pharmaceutical Scientist's Outstanding Graduate Research Award in Pharmaceutical Technologies. Dr. Mirza's current research is focused on engineering of advanced nanosystems for drug delivery applications. In addition, his areas of expertise include pharmaceutical crystallization, cocrystallization and nanocrystallization, droplet-based microfluidics, and solid-state characterization, preformulation and formulation. Overall, his research has attracted around $550 000 in sustained funding from the Academy of Finland, private foundations, and industries. He is the author/coauthor of over 50 peer-reviewed articles and conference proceedings.
Tarun Mandal, Ph.D., McCaffrey/Norwood Endowed Professor of Pharmacy & Director, Center for Nanomedicine & Drug Delivery, College of Pharmacy, Xavier University of Louisiana
Tarun K. Mandal, Ph.D. is an Endowed Professor at Xavier University College of Pharmacy. He is also Adjunct Professor at the UT at Memphis, UL at Monroe, and LSUHSC. He is the founding Director of the Center for Nanomedicine and Drug Delivery and Co-Director of the Louisiana Vaccine Center. He is a member of the Scientific Advisory Board of Autoimmune Technologies. He has been elected as Fellow of the AAPS.His research focuses on the design and development of commercially viable formulations to improve the safety, efficacy, and patient compliance. Cutting-edge research in his laboratory has resulted in controlled release formulations of many therapeutic agents. He has published close to 200 original research papers, reviews, abstracts, and monographs and filed five patents. He received his B.S. degree in Pharmacy and M.S. and Ph.D. degree in Pharmaceutics/Industrial Pharmacy.
Russell G. Burge, Ph.D., Application Scientist, Freeslate, Inc. Russell Burge is an Application Scientist at Freeslate, Inc. He earned a Bachelor of Science degree in biochemistry from Arizona State University in Tempe. Russell obtained a Ph.D. in molecular biology and biochemistry from the Scripps Research Institute in La Jolla, California. After graduation, Russell received post-doctoral training at the University of Colorado in Boulder. During post-doctoral training, Russell worked on the biophysical characterization of RNA and DNA aptamers relevant to the biopharmaceutical industry. Russell's industry experience includes working as a Scientist I at KBI Biopharma Inc., where he worked on more than a dozen biopharmaceutical development projects.
Robert K. Prud'homme, Ph.D., Professor and Director Program in Engineering Biology, Department of Chemical & Biological Engineering, Princeton University
Robert K. Prud'homme is a professor in the Department of Chemical and Biological Engineering at Princeton University and Director of the Engineering Biology Program. He received his BS at Stanford University and his PhD from the University of Wisconsin at Madison under Professor Bob Bird. He has served on the executive committees of the American Institute of Chemical Engineers Materials Science Division and the U.S. Society of Rheology and was the President of the U.S. Society of Rheology. He has served as the chair of the Technical Advisory Board for Material Science Research for Dow Chemical Company, which directs Dow's materials research programs, and he was on the Board of Directors of Rheometric Scientific Inc., the leading manufacturer of rheological instrumentation. He also served on the Nanotechnology Scientific Advisory Committee for BASF, which provided guidance for future trends in nanotechnology for the company. His awards include the NSF Presidential Young Investigator Award, Princeton School of Engineering and Applied Science Outstanding Teaching Award, the Sydney Ross Lectureship at RPI, the Bird,Stewart and Lightfoot Lecturer at the University of Wisconsin, the Dinesh Shah lectureship at the University of Florida, and the Midland Macromolecular Institute Visiting Professor in Midland Michigan. He has been the organizer and Chair of the Gordon Conference on Ion Containing Polymers, and the Society of Petroleum Engineers Forum on Stimulation Fluid Rheology, in addition to organizing numerous sessions at AIChE, ACS, and SOR meetings. He directed the Princeton-University of Minnesota-Iowa State NSF NIRT Center on nanoparticle formation. His research interests include rheology and self-assembly of complex fluids. Systems of interest are biopolymer solutions and gels, surfactant mesophases, and polymer/surfactant mixtures. The goals of the studies are to understand how weak molecular-level interactions can be used to tune macroscopic bulk properties and phase behavior. Application of the work is directed at nanoparticle formation for the drug delivery, controlled release, targeting, and imaging.
Kevin Constable, Director, Technology Development, Global Pharmaceutical Solutions, Terumo Medical Corporation
Ian W. Hunter, Ph.D., Hatsopoulos Professor, Department of Mechanical Engineering, Mechanical Engineering, MIT
Ian W. Hunter is a Chaired Professor (Hatsopoulos Professor) in the Department of Mechanical Engineering at the Massachusetts Institute of Technology (MIT) in Cambridge, Massachusetts where he heads the BioInstrumentation Laboratory. Ian was born in New Zealand and had an early interest in science and instrumentation which continues to the present. By the age of 10 he had published his first paper (a design of a miniaturized single transistor radio) and by 14 had built a fully functional gas liquid chromatograph (hydrogen flame ionization type) for chemical analysis. After graduating from Auckland University with BSc, MSc and PhD degrees he did a Post-Doctoral Fellowship in the Department of Biomedical Engineering at McGill University, Canada. He then joined the McGill University faculty and advanced to tenured Associate Professor in the Department of Biomedical Engineering. In 1994 Ian moved his lab to the Department of Mechanical Engineering at MIT.
His main area of research is in bio-instrumentation. As a result of his research, Ian has over 350 refereed publications. He also invents instruments and devices based on this research. This has led to over 150 issued and pending patents. Ian's inventions have been used by numerous companies and in addition he has founded or co-founded 22 companies. His most recent company, Portal Instruments, is commercializing a very novel, high performance Lorentz force actuated needle-free drug delivery technology invented by Ian and developed in his BioInstrumentation Lab at MIT over a 10 year period.
William J. Lambert, Ph.D., Fellow, Drug Delivery and Device Development, MedImmune, Inc.
Dr. Lambert heads the Innovative Drug Delivery Group at MedImmune, the biologics division of AstraZeneca. His group assesses novel formulation- and device-based approaches to deliver drug and vaccine candidates. Prior to MedImmune, he held various positions at the Upjohn Company, Pfizer, Eisai, and finally Pacira Pharmaceuticals, where he was Sr. VP of Pharmaceutical Development. He is a member of the Advisory Boards of J. Pharm. Sci., AFPE, NIPTE, the Handbook of Pharmaceutical Excipients, and the USP Excipient Expert Committee.
Cindy Wu, Ph.D., Principal Scientist, Pharmaceutical Sciences, Allergan, Inc.
Dr. Wu is a Principal Scientist in the pharmaceutical group at Allergan, working on the development of ophthalmic formulations. She received her B.S. in engineering from Swarthmore College and a Ph.D. in chemical engineering from Northwestern University. Prior to joining Allergan, she worked as a scientist at Amgen on the development of parenteral formulations and drug delivery systems.
Ashim K. Mitra, Ph.D., University of Missouri Curators' Professor of Pharmacy, Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City
Ashim K. Mitra received his Ph.D. in Pharmaceutical Chemistry in 1983 from the University of Kansas. He joined the University of Missouri-Kansas City in 1994 as Chairman of Pharmaceutical Sciences. He is also Vice Provost for Interdisciplinary Research, UM Curators' Professor of Pharmacy, Co-Director, Vision Research Center UMKC School of Medicine. He has over 30 years of experience in the field of ocular drug delivery and disposition. He authored and co-authored over 300 refereed articles, editor of 6 books, 60 book chapters in the area of formulation development and ocular drug delivery, awarded 9 patents, and presented (along with his research group) well over 500 presentations/abstracts at national and international scientific meetings. This work has attracted over six million dollars in funding from government agencies such as the National Institutes of Health (NIH), Department of Defense (DOD) and pharmaceutical companies. He served as Co-chair, of the USP Council of Experts, General Chapter <771> Ophthalmic Preparations Expert Panel U.S. Pharmacopeia. In 2007, he was named one of two recipients for the ARVO/Pfizer Ophthalmic Translational Research Award for excellence in the areas of research and fundamental scientific discoveries, including concepts and novel technologies, leading to clinical evidence of diagnosis, prevention, or amelioration of the pathological eye and/or an understanding of the normal vision processes. He is a recipient of a numbers of research awards from NIH, AAPS, AACP, and numerous pharmaceutical organizations. He has served as a regular member of the National Institute of Health (NIH) Pharmacology & Toxicology Study Section and on the NIH Gene and Drug Delivery Study Section. He also serves on numerous scientific editorial boards. Dr. Mitra's laboratory has been engaged in ocular drug delivery for nearly 30 years. Current efforts are directed to: (1) delineate mechanisms of transscleral permeation of both small and large molecules, (2) develop new strategies to deliver neuroprotective and antiproliferative agents from topical eye drops, (3) to design new biopolymers for long-term topical and subconjunctival administrations and finally, (4) delineate the expression of various transporters and receptor on the cornea, blood-retinal and blood aqueous barrier and utilize these cell absorptive mechanisms to deliver small and large molecule therapeutics.
Rami ElHayek, Ph.D., Research Manager, Research and Development, Ocular Therapeutix, Inc.
Dr. El-Hayek holds a BS in chemistry from the Lebanese University in Beirut, a MS in Chemistry from UMASS Boston then completed his doctoral studies in Chemistry/ Sustainable Material Design at the Center for Green Chemistry at the University of Massachusetts Boston/Lowell in 2008.
Dr. El-Hayek joined the Biomaterials and BioSurgery Group at Genzyme in Cambridge MA as part of the R&D group where he collaborated with some of the most experienced and skilled scientists in the art of Biomaterials, Tissue Engineering and Biosurgical design. Many biomedical applications were explored from Non Fouling Coatings for Implantable Devices and Drug Delivery Systems to Development of Matrices for Cellular Tissue Engineering and Tough Hydrogels as Orthopedic Implants for Meniscal Repair.
Currently facing some new challenges in the field of Ophthalmology at Ocular Therapeutix, a privately held company focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology and ophthalmic surgery. The company's first product, Re-Sure® Ocular Bandage, approved in January 2014, is a synthetic ocular bandage designed and indicated for ophthalmic surgery. Ocular Therapeutix is also developing sustained drug delivery vehicles for the therapy and treatment of ophthalmic diseases. Ocular Therapeutix's vision is to address unmet needs in ophthalmology and ophthalmic surgery by developing first-of-a-kind therapeutic products.
Robert Kelley, Ph.D., Senior Scientist, Drug Delivery, Genentech, Inc.
Dr. Robert F. Kelley earned a Ph.D. in Biochemistry from University of Iowa, with thesis work on protein folding in the lab of Dr. Earle Stellwagen, followed by postdoctoral training at Yale University with Dr. Fred Richards. Since joining Genentech, Bob has worked on a wide range of protein and antibody engineering projects with an emphasis on biophysical characterization of protein stability and protein-protein interactions. He is currently a Senior Scientist in the Drug Delivery Dept. at Genentech focusing on delivery of antibodies to the eye for treatment of ocular disease.
New Technologies for Biologics Delivery and Targeting Conference
Omid Farokhzad, M.D., Associate Professor, Laboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women's Hospital and Harvard Medical School
Omid Farokhzad is an Associate Professor at Harvard Medical School (HMS) and a physician-scientist in the Department of Anesthesiology at Brigham and Women's Hospital (BWH). He completed his post-graduate clinical and post-doctoral research trainings, respectively, at the BWH/HMS and MIT in the laboratory of Institute Professor Robert Langer. He received his M.D. and M.A. from Boston University School of Medicine. Dr. Farokhzad directs the Laboratory of Nanomedicine and Biomaterials at BWH, which he established in 2004. He is a faculty member of the Brigham Research Institute Cancer Research Center at BWH. He is additionally a member of the Dana Farber/Harvard Cancer Center Programs in Prostate Cancer and Cancer Cell Biology. He is a Research Affiliate in the Harvard-MIT Division of Health Sciences and Technology (HST). Dr. Farokhzad has extensive experience with the development of therapeutic nanoparticle technologies; most notably, he pioneered the high throughput combinatorial development and screening of multifunctional nanoparticles for medical applications. Dr. Farokhzad has authored approximately 95 papers and holds more then 125 issued/pending US and International patents. The technologies that Dr. Farokhzad has developed with collaborators at HMS, DFCI, Cornell and MIT have formed the basis for: 1) a new class of targeted nanoparticles for treatment of important human diseases including cancer and cardiovascular disease; 2) a new class of synthetic nanoparticle vaccines for prophylactic and therapeutic applications and 3) a new class of integrative combination nanomedicines for synergistic treatment of cancers, inflammation/pain, and infectious diseases. Dr. Farokhzad has delivered more than 110 invited talks including 85 at national and international conferences; several of which were keynote addresses. He has served as an ad hoc reviewer for over 30 international peer-reviewed journals including serving on the editorial board or advisory board of six journals including Nanomedicine, Theranostics, Drug Delivery, and ChemPlusChem. Dr. Farokhzad was elected to the College of the Fellows of the American Institute of Medical and biological Engineering. He was among the Nano50 winners by NASA Nanotech Briefs, which awards the most innovative people and design ideas that will revolutionize nanotechnology, and was among the 15 recipients across all industries to receive the All Star Distinguished Achievement Award from the Mass High Tech Journal for his contributions to the Life Sciences industry. He was an Ernst & Young Entrepreneur of the Year awardee for the Northeast Region. The Boston Globe selected him among the top innovators in Massachusetts.
Ashutosh Chilkoti, Ph.D., ThePilkington Professor of Biomedical Engineering, Director, Center for Biologically Inspired Materials and Materials Systems, Duke University
Ashutosh Chilkoti received his B. Tech. in Chemical Engineering from the Indian Institute of Technology, Delhi in 1985, a Ph.D. in Chemical Engineering from the University of Washington in 1991, and was a post-doctoral fellow in the Department of Bioengineering at the University of Washington from 1992 to 1995. http://fds.duke.edu/db/pratt/BME/ashutosh.chilkoti He was appointed as an Asst. Prof. of Biomedical Engineering at Duke University in 1996, was promoted to Associate Professor in 2002 and to Professor in 2006. He currently holds the Theo Pilkington Chair in Biomedical Engineering and currently has appointments in three departments at Duke University: Biomedical Engineering, Mechanical Engineering and Materials Science, and Chemistry. Prof. Chilkoti was awarded the CAREER award from the NSF in 1998, the 3M non-tenured faculty award in 2002, and was awarded the Distinguished Research Award from the Pratt School of Engineering at Duke University in 2003 and in 2005. He was appointed Associate Director of the Center for Biologically Inspired Materials and Materials Systems at Duke University in 2002 and Director in 2007. His areas of research include Biomolecular Engineering with a focus on stimulus responsive biopolymers for protein purification and drug delivery, and Biointerface Science, with a focus on the development of advanced coatings for control of protein and cell adhesion for biosensors and biomaterials, bioinspired nanofabrication and plasmonic biosensors. http://www.chilkotilab.pratt.duke.edu/ He has co-authored over 175 publications, has been cited over 5600 times, has an H-index of 44, and has 25 patents awarded or in process. He is co-founder of a start-up company (Phase Biopharmaceuticals Inc.) that has raised over $35 million in venture capital funding, and he serves on the Scientific Advisory Board of another company, Asemblon. He serves on the Editorial Board of three journals: Journal of Biomedical Materials Research, Protein Engineering, Design and Selection, and Biointerphases and is a reviewer for over 20 journals.
Donald Cropek, Ph.D., Scientist, Construction Engineering Research Laboratory, Engineering Research and Development Center, U.S. Army Corps of Engineers
Dr. Donald Cropek is the Director of the Environmental Chemistry Laboratory at the U.S. Army Corps of Engineers, ERDC-CERL, in Champaign, IL. He has also initiated the Synthetic Biology Laboratory at CERL that takes advantage of his group's expertise in microbiology, molecular and cell biology, and analytical chemistry. He received his Ph.D. in Analytical Chemistry from the University of Illinois, Urbana-Champaign (UIUC). Dr. Cropek is also affiliated with the Chemistry and Veterinarian Biosciences Departments at UIUC as well as with the Illinois Natural History Survey. His experience began primarily to address short-term environmental and compliance issues at military installations, but has steadily moved to a focus on basic and applied research in biosensing. His group comprises molecular and cell biologists, tissue engineers, microbiologists, polymer and analytical chemists, and civil engineers that study integrated microfluidic systems, tissue engineering, novel environmental sensor design, innovative selective molecular beacons, and advanced oxidative treatment methods for contaminants.
Mansoor M. Amiji, Ph.D., Distinguished Professor and Chairman, Dept. of Pharmaceutical Sciences, School of Pharmacy, Northeastern University
Dr. Amiji is currently the Distinguished Professor and Chairman of the Department of Pharmaceutical Sciences and Co-Director of Northeastern University Nanomedicine Education and Research Consortium (NERC) at Northeastern University in Boston, MA. NERC oversees a doctoral training grant in Nanomedicine Science and Technology that was co-funded by the National Institutes of Health (NIH) and the National Science Foundation (NSF). Dr. Amiji received the BS degree in Pharmacy from Northeastern University in 1988 and a PhD in Pharmaceutical Sciences from Purdue University in 1992.
His research is focused on development of biocompatible materials from natural and synthetic polymers, target-specific drug and gene delivery systems for cancer and infectious diseases, and nanotechnology applications for medical diagnosis, imaging, and therapy. His research has received over $15 million in sustained funding from the NIH, NSF, private foundations, and corporations.
Dr. Amiji teaches in the professional pharmacy program and in the graduate programs of Pharmaceutical Science, Biotechnology, and Nanomedicine. He has published four books and over 200 book chapters, peer-reviewed articles, and conference proceedings. He has received a number of awards including the NSTI Award for Outstanding Contributions towards the Advancement of Nanotechnology, Microtechnology, and Biotechnology in 2006 and the AAPS Fellowship and the AAPS Meritorious Manuscript Award in 2007.
Ramin Darvari, Ph.D., Principal Research Scientist II, Novel Delivery Technologies, Pfizer, Inc.
Marian Gindy, Ph.D., Director, Pharmaceutical Sciences, Merck Research Laboratories
Marian earned her BS in Chemical Engineering from Rutgers University and PhD in Chemical and Biological Engineering from Princeton University. She joined Merck in 2000 working in Chemical Engineering R&D where she was responsible for supporting the development and optimization of synthetic processes for the manufacturing of active pharmaceutical ingredients. During her tenure, she was a key contributor and leader of multiple small molecule discovery and development programs. She is currently a Director of Pharmaceutical Sciences, where she leads the formulation design and manufacturing process development of siRNA delivery vehicles to enable lead ID, optimization and early phase clinical development of siRNA therapeutics.
Andrea Leone-Bay, Ph.D., Vice President, Pharmaceutical R&D, MannKind Corp.
Andrea Leone-Bay holds a Ph.D. in Organic Chemistry and has worked in the pharmaceutical industry for over 25 years. She has published 47 manuscripts in peer-reviewed journals and is an inventor on 87 issued U.S. patents. Her primary areas of expertise include chemistry and formulations research and development for oral and inhaled drug delivery. In particular, Andrea is interested the development of formulation/device combination products for the oral inhalation delivery of peptides, proteins and small molecule drugs for diabetes, osteoporosis, asthma and COPD. Andrea is currently Vice President of Pharmaceutical Research & Development at MannKind Corporation, where she and her staff are focused on the development of pulmonary drug delivery technologies.
Ajay K. Banga, Ph.D., Professor and Department Chair, Pharmaceutical Sciences, Endowed Chair in Transdermal Delivery Systems, College of Pharmacy, Mercer University
Dr. Ajay K. Banga has a Ph.D. in pharmaceutical sciences from Rutgers University in NJ and currently is Professor and Chair in the Department of Pharmaceutical Sciences at the College of Pharmacy, Mercer University, Atlanta, GA. He also holds an Endowed Chair in transdermal delivery systems. His transdermal delivery laboratory has been funded by several companies to explore non-traditional approaches for topical/transdermal drug delivery and he has over 275 publications and scientific abstracts in this area of research. Dr. Banga currently serves on the Editorial Board of 10 journals, as Associate Editor for one journal, and has served as the Editor-in-Chief for a drug delivery journal. He has written three books in the areas of delivery of proteins and transdermal delivery. He is a Fellow of the American Association of Pharmaceutical Scientists.
Hayat Onyuksel, Ph.D., Professor of Pharmaceutics and Bioengineering, Department of Biopharmaceutical Sciences, College of Pharmacy, University of Illinois
Dr. Hayat Onyuksel is currently Professor of Pharmaceutics and Bioengineering at the University of Illinois at Chicago (UIC), Department of Biopharmaceutical Sciences, College of Pharmacy. Her research interest is in the area of targeted drug delivery. She uses lipid-based nano carriers to develop nanomedicines with improved drug solubility, stability and safety. Applying her innovative targeted approach she has prepared several peptide nanomedicines and showed on animal models successful treatments of cancer and inflammatory diseases. Dr. Onyuksel has published more than 300 publications including scientific journal papers, conference proceedings, abstracts, and 9 issued patents.
She has received several prestigious awards including New Investigator Award from American Association of Colleges of Pharmacy, the UIC Inventor of the Year Award, the UIC Woman of the Year Award, UIC Graduate Mentoring Award, UIC University Scholar, and AAPS Lipid Based Drug Delivery Outstanding Researcher Award . She is a UIC University Scholar and AAPS fellow. Dr. Onyuksel has been serving in several NIH grant review panels more than two decades, she was a regular member of newly formed NIH Nano study session during 2009-2011. She was an associate editor of the Journal Nanomedicine: Nanotechnology, Biology, and Medicine between 2011-2013. She is currently on the Editorial Board of nine scientific journals related to nanotechnology and pharmaceutical sciences.
Maya Salnikova, Ph.D., Senior Scientist, Lead for Process and Product Development, Novartis Vaccines & Diagnostics, Inc.
Maya Salnikova Ph. D., is an expert in the product and process development, including novel drug delivery approaches for biologics, biosimilars and vaccine. Currently, she leads technical teams on Process and Product Development for novel vaccines at Novartis Vaccines and Diagnostics. In past, Dr. Maya led formulation and drug product development of biologics, biosimilars and vaccines at Merck for 5 years. At Macromolecule and Vaccine Stabilization Center (at University of Kansas) she contributed to biophysical characterization and development of Clostridium difficile vaccine as well as design for lyophilization platforms for growth hormone. Having earned her Ph.D. in pharmaceutical science from University of Kansas, Dr. Salnikova has authored several patents, peer-reviewed scientific publications, review articles and book chapters. She has presented at several international conferences and chaired scientific workshops.
Reinhard Gabathuler, Ph.D., Chief Scientist, biOasis Technologies Inc.
Dr Gabathuler obtained his PhD in Plant Biochemistry at the Université de Lausanne, Switzerland, in 1982. He completed postdoctoral studies at the University of Washington, Seattle, WA, USA. He became a research fellow at the Swiss Institute for Cancer Research (ISREC) in Lausanne and at the Ludwig Institute for Cancer Research at the Karolinska Institutet in Stockholm. In 1991, he joined the Biotechnology Laboratory of the University of British Columbia in Vancouver, Canada.
His research on new vector for delivery of therapeutics to the brain led to the creation of Synapse Technologies Inc., where he began as Director of Blood Brain Barrier Research, ultimately rising to the position of Vice President of Research. BioMarin Pharmaceutical Inc. later acquired the company, where Dr Gabathuler assumed the position of Vice President, Brain Research.
Dr Gabathuler joined AngioChem Inc. in 2004 as Chief Scientific Officer and is now the Chief Scientist of biOasis Technologies Inc. for the development of new peptide vector, Transcend, for the brain delivery of biologics.
Scott Banta, Ph.D., Associate Professor, Department of Chemical Engineering, Columbia University
Dr. Banta is Associate Professor of Chemical Engineering and director of the Protein and Metabolic Engineering Laboratory at Columbia University. His research thrusts are aimed at the engineering of novel proteins and peptides for a variety of important applications, including drug delivery, energy production, biosensing, bionanotechnology, and bioseparations.
Pankaj Karande, Ph.D., Assistant Professor, Department of Chemical & Biological Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute
Prof. Karande joined the Chemical and Biological Engineering Department at Rensselaer in 2008. Before joining Rensselaer, Prof. Karande was a Postdoctoral Fellow in the Chemical Engineering Department and Center for Cancer Research at Massachusetts Institute of Technology. His postdoctoral research focused on targeted drug delivery to tumors using serum proteins such as albumin as drug carriers. He obtained his Ph.D. from UC Santa Barbara in 2006 where his thesis work focused on the use of chemical enhancers for transdermal drug delivery. Prof. Karande has received several awards for his work including The Edison Award for best Product in Science and Medicine (2009), The Anna Fuller Fellowship in Molecular Oncology (2006-2007), Outstanding Pharmaceutical Paper by the Controlled Release Society (2005) and the Goldhirsh Brain Tumor Foundation Research Award (2010). Prof. Karande is an inventor on several patents in the area of Transdermal Formulation Discovery, Novel High Throughput Screening Platforms, and Drug Delivery Systems. He has also served as a scientific advisor to fqubed Inc., a soft materials innovation company (now part of Nuvo research).
Per-Ola Freskgard, Ph.D., Senior Leader and Vice Director, Neuroscience, Roche
Per-Ola Freskgard is currently a Senior Leader in Neuroscience, Pharma Research and Early Development (pRED) ROCHE. He has a Ph.D. in Biochemistry and a post-doctoral visiting associate at California Institute of Technology, Chemical Engineering. 20 years of experience in big pharma and small biotech companies.He has authored or co-authored more than 60 peer reviewed international journals and patent applications in the fields of protein engineering, DNA encoding of small molecules, thrombosis and haemostasisand neuroscience.
Christopher A. Rhodes, Ph.D., President, Christopher A. Rhodes & Associates LLC
Dr. Rhodes is a pharmaceutical technologist with experience in combination product development including formulations and devices for pulmonary inhalation aerosol, nasal spray, transdermal patch, sustained release injection, and oral delivery systems for biopharmaceutical products and small molecules.
Dr. Rhodes has been responsible for product development including drug delivery R&D, formulation and process development, clinical supply and manufacturing, analytical and bioanalytical chemistry in companies including SKS Ocular, Amylin Pharmaceuticals, Guilford Pharmaceuticals, and Mannkind Pharmaceuticals.Currently, Dr. Rhodes is President and Founder of a consulting practice providing interim management, R&D support, portfolio strategy, and due diligence to biopharmaceutical, drug delivery, device, and specialty pharmaceutical companies in combination product development and integration with commercial strategy and life cycle plans.
Dr. Rhodes earned his Doctorate degree in physical organic chemistry from UCLA and completed his training with a Post Doctoral position at Yale University. He has a Bachelors degree in chemistry from New York University.
Frank Tagliaferri, Ph.D., Vice President, R&D, 4P Therapeutics
Frank Tagliaferri is currently Vice President of Research & Development at 4P Therapeutics in Norcross, GA working on the development and commercialization of novel drug delivery products. He received his Bachelor's degree from Franklin&MarshallCollege in 1987 and his Ph.D. in Chemistry from Universityof Virginia in 1992. He was a post-doctoral fellow at University of Tennessee, Knoxville from 1992-1995. As Director of Drug Delivery at GeneMedicine (later Valentis) from 1995-2001 his focus was on the development of delivery systems for both DNA and proteins. He later served as Director of Delivery and Preclinical Development at Napro Pharmaceuticals (later Tapestry) from 2001-2003 where he worked on a variety of cell and oligonucleotide therapeutics. He was at Altea Therapeutics in Atlanta, GA from 2003 to 2011 where he most recently served as Vice President of R&D. While at Altea he helped to develop the PassPort® System for the transdermal delivery of small molecules and biologics. His research interests include the design, characterization, and development of novel delivery systems and drug/device combination products for biologics and other complex molecules.
Christopher M. Olsen, Ph.D., Senior Scientist, CMC Analytical Chemistry, Alcon Laboratories, Inc., a Division of Novartis
Dr. Christopher Olsen is a Senior Scientist in the CMC Analytical Chemistry group at Alcon Labs (a Novartis company), completed his undergraduate studies in physics and chemistry from the University of Nebraska-Omaha (B.S. in Chemistry, 2000), and received his Ph.D. in Pharmaceutical Sciences from the University of Nebraska Medical Center in 2008 with a focus on the biophysical characterization of unique nucleic acid structures. Dr. Olsen completed his postdoctoral fellowship in 2010 studying the formulation and bio physical characterization of biopharmaceuticals at the Macromolecule and Vaccine Stabilization Center at the University of Kansas. He continued as a permanent staff member and research associate of the Center until 2012, and in early 2012 moved to Alcon to join the biologics group where he continues to work as an analytical chemist in the biologics division and as a CMC Team lead for a biopharmaceutical product.
Dr. Olsen's experiences include the formulation and biophysical characterization of over 15 biopharmaceuticals ranging from small peptides to mAbs at both low and high concentration, vaccines, live attenuated viruses, G-quadruplexes, and siRNAs for an assortment of small and large pharmaceutical companies. He has also worked with the development, design and testing of new temperature dependent, automated and high throughput instrumentation for a variety of techniques including Calorimetry, Spectroscopy, and Fluorometry. His work at Alcon involves the development, performance and validation of bio-analytical assays in a GMP environment; supports exploratory, toxicology, and clinical stability studies; writes and reviews briefing documents, IND and CTA Amendments; works closely with CROs and CMOs for Phase III commercial drug supply; is an active member of 5-6 CMC sub teams within Alcon and is the CMC Team lead for one of the active biopharmaceutical projects.
Nicholas J. Darton, Ph.D., Platform Manager, Arecor Ltd.
Nicholas Darton is responsible for managing and developing new formulation technologies. He has a strong background in the research and development of novel platform technologies in industry and academia. He is currently responsible for R&D activities in new platform development areas and technical IP support in the field of stabilisation of biologics with a key focus on rheology. He had developed a new chromatography platform based on extruded plastic microcapillary films for single-step antibody purification, as a Research Associate at the Department of Chemical Engineering and Biotechnology, University of Cambridge. He has tested this new chromatography platform in close collaboration with Medimmune, Cobra Biologics, Paraytec and Lonza, gaining three BBRSC-BRIC prizes 2010-2012. Dr. Darton is also an Inventor of a new drug-delivery platform using magnetic nanoparticles to deliver linked therapeutics by MRI in 2008 as a Research Associate, Department of Chemical Engineering, University of Cambridge. He was awarded a Ph.D. in Biochemistry at the University of Cambridge in 2003 for Wellcome Trust Prize funded research into a peptide-loop phage display vaccine platform technology. He is a member of the Royal Society of Chemistry/Society of Chemical Industry's Joint Colloids Committee and an Associate Member of Institute of Chemical Engineers.
250 First Avenue, Suite 300
Needham, MA 02494
E: email@example.com
Innovation Portals
Biological Therapeutic Products
Biomarkers & Diagnostics
Biopharma Strategy
Bioprocess & Manufacturing
Clinical Trials & Translational Medicine
Drug & Device Safety
Drug Discovery & Development
Drug Targets
IT & Informatics
Technology & Tools For Life Science
Therapeutic Indications
CII Divisions
Cambridge Healthtech Institute
Cambridge EnerTech
Business Development
Corporate Information
Cambridge Innovation Institute
Executive Team
Mailing List
Request Information
Privacy Policy


text:
She's a bi-coastal, award-winning country singer, but she calls the East Coast home, and we're happy to report that Doreen Taylor is back in Pennsylvania and treating her fans to a big show at the World Cafe in Philly!
Doreen and some members of her band stopped by 69 News to give us a preview on Music Monday.
WORLD CAFE LIFE TICKETS: http://doreentaylorlive.brownpapertickets.com


text:
David Lynch, the undisputed wizard of odd as writer-director of Eraserhead, The Elephant Man and Dune, has topped himself with a cuckoo classic. Funny and frightening, the film only occasionally makes sense. Even so, the feverish, erotically charged atmosphere is impossible to shake. Kyle MacLahlan, the stalwart hero of Dune, stars as a college student visiting his sick dad in North Carolina. The setting is a small lumber town, the kind with a chirpy radio weatherman who, on a sunny day, advises listeners to "get out your chainsaws." Shortcutting through a field one afternoon, MacLahlan finds a freshly severed human ear. The police thank him for bringing in the appendage, but offer no explanation. His curiosity aroused, MacLahlan coaxes a few clues out of a cop's smitten teenage daughter, a tremulous Laura (Smooth Talk) Dern. The clues lead to a voluptuous nightclub singer, played with torchy carnality by Isabella (White Nights) Rossellini. This is the point where the film and probably most audiences come unglued. In a smokey bistro Rossellini sings endless off-key choruses of the old Bobby Vinton hit Blue Velvet. Perhaps in revenge, a drug-pushing psycho, played by Dennis (Easy Rider) Hopper, bursts into Rossellini's apartment to force huge chunks of a blue velvet robe down her throat before sexually assaulting her. Hopper has kidnapped her husband and son to insure her continued submission. Later, Rossellini at knifepoint forces amateur sleuth MacLahlan to strip and make love to her. He obliges, balks when she asks to be beaten to heighten her arousal, then obliges again. In short order the Eagle Scout is sucked into a vortex of violent crime and perversion. Despite absurd situations and the dippiest dialogue this side of The Rocky Horror Picture Show, the movie makes for vivid visual storytelling. Whether you are attracted or repelled by Lynch's bizarre vision, one thing is for sure: You've never seen anything like it in your life. (R)
Picks and Pans Review: Blue Velvet
updated 09/22/1986 AT 01:00 AM EDT
•originally published 09/22/1986 AT 01:00 AM EDT